This case series measured the results of using upadacitinib for moderate or severe cases of epidermolysis bullosa pruriginosa.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: